Whilst 20-55% of patients with a diagnosis of Whipple's disease have clinically evident cardiac manifestations, 4 in very few reported cases has the initial presentation been valvular heart disease. 5,6 Paravalvular abscess formation, seen in the present case, does not seem to have been reported in Whipple's endocarditis. Once diagnosed, Whipple's disease can be successfully treated with 1-2 years of agents such as cotrimoxazole.
If the NICE guidance on chest pain of recent onset had been implemented in our study population, the need for change of the offer of specific first line tests (as discussed above) means that, a major re-organisation in both the services in RACPCs and the current process of referral to these specialists cardiac services from the primary care physicians will be required. Whilst acknowledging that regional variations may exist in the proportions of tests needed (depending on the incidence and prevalence of CAD and risk factors), these figures from our study represent a much higher level of need of these specialist tests for patients attending RACPCs than initially suggested by contemporary reviews. We therefore conclude that data from larger studies in many regions may be useful for understanding the degree of regional and national changes required for organising the structure and referrals to specialist cardiac services in Scotland, if an equitable service based on NICE guidance 95 is rolled out throughout United Kingdom in future.
The causal organism in Whipple's disease, a rare disorder with characteristic duodenal and jejunal changes, was first cultured in 2000. 1 Although cardiac involvement is common in Whipple's, it is seldom an isolated finding.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.